C16 Ganglioside GM3-d9 (d18:1/16:0-d9) (ammonium salt) (Synonyms: C16 GM3-d9, N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-Monosialoganglioside GM3)

C16 Ganglioside G_M3-d₉ (d18:1/16:0-d₉) is intended for use as an internal standard for the quantification of C16 ganglioside G_M3 by GC- or LC-MS. C16 Ganglioside G_M3 (d18:1/16:0) is a monosialylated ganglioside. It has been found in human fetal frontal lobe tissue isolated in the 27^th gestational week but not in human fetal anencephalic residual brain tissue isolated in the 28^th gestational week.¹ C16 Ganglioside G_M3 (d18:1/16:0) is higher in the serum of patients with visceral fat accumulation (VFA) and patients with VFA and dyslipidemia compared to healthy lean control subjects.² Serum levels of C16 ganglioside G_M3 (d18:1/16:0) are inversely correlated with erythrocyte counts in patients with hematological diseases, including patients with lymphoid neoplasms.³ [Matreya, LLC. Catalog No. 2059]

1.Almeida, R., Mosoarca, C., Chirita, M., et al.Coupling of fully automated chip-based electrospray ionization to high-capacity ion trap mass spectrometer for ganglioside analysisAnal. Biochem.378(1)43-52(2008) 2.Veillon, L., Go, S., Matsuyama, W., et al.Identification of ganglioside GM3 molecular species in human serum associated with risk factors of metabolic syndromePLoS One10(6)e0129645(2015) 3.Nishikawa, M., Kurano, M., Nitta, T., et al.Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseasesSci. Rep.9(1)6308(2019)